DarioHealth touts analysis on digital therapeutics for diabetes sufferers


At home ” DarioHealth promotes research into digital therapeutics for diabetes patients

DarioHealth (NSDQ: DRIO) announced today that recently published research supports its digital therapy platform for type 2 diabetes.

New York-based DarioHealth published a new study through a letter to the editor in the Journal of Diabetes Science and Technology, according to a press release. The study tracked participants who used DarioHealth’s digital therapeutics to treat diabetes and monitored both clinical and self-reported effects.

You can find the full story on our sister site Drug Delivery Business News.

Reader interactions